New hope in the fight against cancer: Can Ivonib cure cancer?

Ivosidenib (Ivosidenib) is a drug that targets genetic mutations and is mainly used to treat patients with certain types of acute myeloid leukemia (AML) and cholangiocarcinoma. However, whether cancer can be cured depends on many factors, including the patient's condition, type of genetic mutation, treatment regimen, physical condition, etc. At the same time, patients also need to maintain a positive attitude, cooperate with the doctor's treatment, and follow the doctor's advice and guidance.

Currently, ivonib has shown certain efficacy in patients with certain types of acute myeloid leukemia (AML) and cholangiocarcinoma, but it does not guarantee that all patients can be cured. In a phase III trial, ivosidenib improved progression-free survival (2.7 months vs. 1.4 months) (p<0.0001) and overall survival (OS) in previously treated patients with IDH1-mutated cholangiocarcinoma, with the median OS in the ivosidenib group being 10.8 months. In addition, the use of this drug also needs to be carried out under the guidance of a doctor and combined with other treatment measures, such as chemotherapy, radiotherapy, etc.

The original version of ivonib has been launched in China, but it is not covered by medical insurance. The price of domestically sold specifications0.25g*60 tablets per box is as high as 100,000 yuan, while the price of the original American version sold overseas is as high as more than 200,000 yuan per box (the price may fluctuate due to exchange rates). Generic drugs of Ivonib are also sold overseas. Their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 250mg*60 tablets produced by a Laos pharmaceutical factory may be more than 6,000 yuan per box (the price may fluctuate due to the exchange rate), and the price is relatively cheap.